All Pharma News
price-trendAsk Us
KAHR and Cancer Focus Fund Begin Dosing in Phase 1b Trial of DSP107

KAHR and Cancer Focus Fund Begin Dosing in Phase 1b Trial of DSP107
PRNEWSWIRE
17 Feb 2022
Share Share
An Israeli biotech is looking to make its name in the jam-packed CD47 space

An Israeli biotech is looking to make its name in the jam-packed CD47 space
Nicole DeFeudis ENDPTS
16 Jun 2021
Share Share
Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect

Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect
N. P. Taylor FIERCEBIOTECH
16 Jun 2021
Share Share
KAHR Announces $46.5 Million Financing for Immunotherapeutic Pipeline

KAHR Announces $46.5 Million Financing for Immunotherapeutic Pipeline
PRNEWSWIRE
16 Jun 2021
Share Share